Research programme: precision oral anticoagulants - Verseon

Drug Profile

Research programme: precision oral anticoagulants - Verseon

Alternative Names: PROACs; Thrombin inhibitors - Verseon; VE 2851; VE-DTIs

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Verseon
  • Class Anticoagulants
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute coronary syndromes; Stroke; Venous thrombosis

Most Recent Events

  • 15 Nov 2017 Verseon plans a clinical trial for VE 2851 in 2018
  • 15 Nov 2017 Preclinical data in Cardiovascular disorders presented at the 90th Annual Scientific Sessions of the American Heart Association (AHA-2017)
  • 30 Nov 2016 Pharmacodynamics data from preclinical trials in Venous Thrombosis released by Verseon
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top